NCT05970718

A Trial to Learn if Different Doses of REGN7544 Are Safe in Healthy Adult Participants

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of REGN7544, an Antagonistic Monoclonal Antibody to NPR1, in Healthy Adults

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: Regeneron Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The study is researching an experimental drug called REGN7544.The study is focused on healthy adults. The aim of the study is to see how safe and tolerable the study drug is in healthy adults. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in your blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	REGN7544	Solution for single ascending Intravenous (IV) or Subcutaneous (SC) administration
DRUG	Matching Placebo	Solution for single ascending IV or SC administration per the protocol

Timeline

• Start date: 2023-08-07
• Primary completion: 2024-07-22
• Completion: 2024-07-22
• First posted: 2023-08-01
• Last updated: 2024-08-12

Locations

1 site across 1 country: New Zealand